Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system

Volume: 84, Pages: 106601 - 106601
Published: Jul 1, 2020
Abstract
• It is the most extensive collection of colitis following the use of ICIs to date based on FAERS. • Significant ROR, PRR, IC, and EBGM emerged for ICI monotherapies and combination therapies. • ICIs were associated with adverse events of colitis. • Practitioners should consider the factors that may increase the likelihood of colitis. Although colitis has been reported in patients treated with immune checkpoint inhibitors (ICIs), associations...
Paper Details
Title
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
Published Date
Jul 1, 2020
Volume
84
Pages
106601 - 106601
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.